IAP6 Rec'd PCT/PTO 23 JUN 2006

## FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 678112403 Express Mail Label Number 23 June 2006 Date of Deposit

Form PTO-1390-MOD (REV 10-96) U. S. Department of Commerce Patent and Trademark Office ATTORNEY'S DOCKET NUMBER 33577-US-PCT U.S. APPLICATION NO. (If known, see 37 CFR 1.5) TRANSMITTAL LETTER TO THE UNITED STATES 0/584369 DESIGNATED/ELECTED OFFICE (DO/EO/US) **CONCERNING A FILING UNDER 35 U.S.C. 371** INTERNATIONAL APPLICATION NO. PRIORITY DATE CLAIMED INTERNATIONAL FILING DATE PCT/SI2004/000046 27 December 2004 (27.12.04) 29 December 2003 (29.12.03) TITLE OF INVENTION SYNTHESIS OF OPTICALLY PURE (R)-5-(2-AMINOPROPYL)-2-METHOXYBENZENESULPHONAMIDE APPLICANT(S) FOR DO/EO/US BARBARA MOHAR Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.  $\boxtimes$ 1. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay 3. examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority  $\boxtimes$ 4. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) 5.  $\boxtimes$ a.  $\square$  is transmitted herewith (required only if not transmitted by the International Bureau). has been transmitted by the International Bureau. (See Form PCT/IB/308) c. is not required, as the application was filed in the United States Receiving Office (RO/US). A translation of the International Application into English (35 U.S.C. 371(c)(2)). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C.371(c)(3)). are transmitted herewith (required only if not transmitted by the International Bureau). have been transmitted by the International Bureau. b. 🔲 have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)). A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11. to 16. below concern document(s) or information included. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment. An Application Data Sheet under 37 CFR 1.76. A substitute specification. 16. A change of power of attorney and/or address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825. 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4). 19. A second copy of the English language translation of the International application under 35 U.S.C. 154(d)(4). 20. 

Other items or information: unexecuted declaration and copy of International Search Report, (1) reference

## IAP20 Rec'd PCT/PTO 23 JUN 2006

U.S. APPLICATION NO	TION NO. (if trown), see 37 CFR 1.5) INTERNATIONAL APPLICATION NO. ATTORNEY'S PCT/S12004/000046 33577-US						DOCKET NUMBER		
The following fe			1.0.	1012001/000010			CALCULAT	IONS PTO U	SE
1110 10110111119 101	<b></b>						ONLY		
21.									
22. Examination Fee									
☐ If International preliminary examination report was prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4)									
and all claims satisfy provisions of FCT Afficie 35(1)-(4)									
All other situations									
23. Search fee									
☐ If Search fee (37 CFR 1.445(a)(2)) has been paid on the international									
application to the USPTO as an International Searching Authority \$  ☑ If International Search Report was prepared and provided to the Office \$400									
All other situations									
TOTAL OF 24 22 AND 22 =								0	
TOTAL OF 21, 22 AND 23 =  Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing)									
program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.									
Total Sheets	Extra s	,		ch additional 50 or fractio	١	RATE			
- 100 =		1 /50 =	thereof (round	d up to a whole number)	X :	\$ 250	\$		
Surcharge of \$130 for furnishing the oath of declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).									
CLAIMS	earliest C	NUMBE	R FILED	NUMBER EXTRA		RATE			
Total claims 20			- 20 =	0	X \$	50	\$		
Independent claims 4			- 3 = (if applicable)	11	X \$	200 360	\$ 20	0	
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$ 360  TOTAL OF ABOVE CALCULATIONS =							\$ 110	0	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be							_		
filed (Note 37 CFR 1.9, 1.27, 1.28).								_	
SUBTOTAL =  Processing fee of \$130 for furnishing the English translation later than 30 months from the								0	
earliest claimed priority date (37 CFR 1.492(f)).									
TOTAL NATIONAL FEE =								0	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied									
by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +  TOTAL FEES ENCLOSED =								0	
TOTAL FEED ENGLOSED -									
							Amount to be: refunde		
							charge	d \$	
a. A check in the amount of \$ to cover the above fees is enclosed.									
b.   Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$1100 to cover the above fees. A duplicate copy of this form is enclosed.									
c.   The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.									
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.									
Send all correspondence to the address associated with Customer No. 001095, which is currently:									
Joseph T. Majka Novartis Attorney for Applicant									
Corporate Intellectual Property Reg. No. 30,570									
One Health Plaza, Building 104 (609) 627-8508 East Hanover, NJ 07936-1080									
East Hallovel, 145 07 300-1000									